Related to Avila Advances Candidate in Deal with Clovis and Inks Separate Agreement with NIAID

• Vertex Grows HCV Pipeline with Purchase of ViroChem
  
• Clovis Oncology Raises $145M in Start-Up Financing
  
• DxS and Boehringer Ingelheim to Offer a Companion Diagnostic for Potential NSCLC Drug
  
• Northeast Biodefense Center Pockets $46M from the NIAID
  
• Lumavita’s Series A Financing Reaches $22.2M in Preparation of Vaginitis Product Launch
  
• Presidio Secures $27M to Advance Preclinical Assets
  
• Vertex Contemplates Giving Up Milestones Worth $250M for a One-Time Cash Payment
  
• Tarceva Given after Initial Chemotherapy Improves Survival in NSCLC Patients
  
• Mitsubishi Tanabe Expands Commercial Rights to Vertex’ HCV Candidate with $105M Up Front
  
• DxS to Provide a Companion Diagnostic for AstraZeneca’s NSCLC Drug
  
• Scientists Discover Marker for HCV
  
• Crucell Wins $40.7M NIAID Contract to Develop Human Flu mAbs
  
• GenVec Obtains $2.5M to Enhance Vector Production Technology
  
• Abbott to Develop Molecular Companion Diagnostic for Pfizer’s NSCLC Drug Candidate
  
• Lilly Allies with Almac to Develop a Companion Diagnostic for NSCLC Drug
  
• Researchers Pinpoint Genetic Alteration That Is Strongly Associated with the Ability to Get Rid of HCV
  
• Antigen Discovery Scores $1.8M from NIAID to Develop Chlamydia Vaccine
  
• Vertex to Receive $155M Tied to HCV Drug’s Clinical and Commercial Success in Europe
  
• Human Genome Sciences Earns $75M from Novartis as HCV Drug Gets Prepared for Regulatory Submissions
  
• NIAID Commissions GenVec for HIV and Influenza Vaccine Development for $2.6M